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http://dx.doi.org/10.1016/j.ccr.2012.05.023SUMMARYIncreased expression of the chemokine CCL2 in tumor cells correlates with enhancedmetastasis, poor prog-
nosis, and recruitment of CCR2+Ly6Chi monocytes. However, the mechanisms driving tumor cell extravasa-
tion through the endothelium remain elusive. Here, we describe CCL2 upregulation in metastatic UICC stage
IV colon carcinomas and demonstrate that tumor cell-derived CCL2 activates the CCR2+ endothelium to
increase vascular permeability in vivo. CCR2 deficiency prevents colon carcinoma extravasation and metas-
tasis. Of note, CCR2 expression on radio-resistant cells or endothelial CCR2 expression restores extravasa-
tion andmetastasis inCcr2/mice. Reduction of CCR2 expression onmyeloid cells decreases but does not
prevent metastasis. CCL2-induced vascular permeability and metastasis is dependent on JAK2-Stat5 and
p38MAPK signaling. Our study identifies potential targets for treating CCL2-dependent metastasis.INTRODUCTION
Metastasis, the spread of tumor cells to vital organs, is the
leading cause of cancer-related death in humans (Gupta and
Massague´, 2006). Understanding the mechanisms drivingSignificance
Metastasis is the primary cause of cancer-related mortality. Ele
and enhances metastasis. We show that metastatic UICC stag
and in vitro models, we demonstrate that colon carcinoma-de
dependent on JAK2-Stat5 and p38MAPK phosphorylation. Ou
vascular permeability and enables efficient tumor cell extravasa
tumor cell extravasation. Moreover, we identified two targets fo
tion during colon carcinoma metastasis. Chemokine-dependen
to occur in various cancers.metastasis is therefore essential for developing new therapeutic
strategies. Metastasis is a multistage process comprising tumor
cell dissemination, survival in the circulation, extravasation, and
ultimately colonization of distant organs (Chambers et al., 2002;
Joyce and Pollard, 2009). Tumor cell extravasation, colonizationvated expression of CCL2 attracts CCR2+Ly6Chi monocytes
e IV colon carcinomas upregulate CCL2. Using both in vivo
rived CCL2 activates endothelial cells through CCR2 and is
r results show that a tumor cell-derived chemokine induces
tion, suggesting a so-far undescribed role for chemokines in
r the suppression of CCL2-dependent tumor cell extravasa-
t control of vascular permeability during metastasis is likely
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Figure 1. CCR2 Determines Susceptibility to Experimental Lung Metastasis in a Dose-Dependent Manner
(A) Macroscopy of lungs derived from C57BL/6 (n = 9), Ccr2+/ (n = 5), Ccr2/mice (n = 9) on day 28 p.i. with MC-38GFP cells. Size of scale bar is indicated (left
panel). Quantification of tumor load by GFP fluorescence in lung homogenates (right panel).
(B) Histological analysis of colon carcinoma tumors (MC-38GFP) in C57BL/6 andCcr2/ lungs at 28 d.p.i. Low and highmagnifications (scale bars) are indicated.
H&E, hematoxylin and eosin; GFP, tumor cells; Ki67, proliferating cells; CD3, T cells; F4/80, macrophages, B220: B cells.
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Tumor Cell-Derived CCL2 Controls Metastasisas well as outgrowth are considered to be the limiting steps in
metastasis (Chambers et al., 2002). It has long been recognized
that the tumor cell microenvironment, composed of fibroblasts,
endothelial cells, and leukocytes, significantly contributes to
metastatic dissemination (Joyce and Pollard, 2009). In particular,
myeloid-derived monocytes/macrophages, commonly found in
various types of malignant cancers were shown to facilitate
tumor cell extravasation and metastatic outgrowth (Peinado
et al., 2011; Qian and Pollard, 2010). Analysis of the metas-
tasis-supporting niche revealed that soluble factors derived
from the local environment and from tumors are responsible
for mobilization of bone marrow (BM)-derived cells during
metastasis (Peinado et al., 2011).
Chemokines and their receptors were found to be involved in
metastasis and also to be direct targets of oncogene activation
(Allavena et al., 2011; Hiratsuka et al., 2006). Stromal cells, infil-
trating leukocytes and tumor cells themselves were identified as
sources of cytokines and chemokines, both at primary tumors
and metastatic sites (La¨ubli and Borsig, 2010; Mishra et al.,
2011; O’Hayre et al., 2008). Highly metastatic cells have been
shown to induce BM-derived macrophages to express cyto-
kines and chemokines emphasizing the role of a reciprocal
crosstalk of tumor cells with the microenvironment to actively
shape the metastatic niche (Kim et al., 2009). Local activation
of endothelia by metastasizing tumor cells induced CCL5
expression, which was associated with monocyte recruitment
during the initial phase of metastasis. Accordingly, inhibition
of CCL5 reduced metastasis (La¨ubli et al., 2009). Recently,
CCL2 has been identified as the major factor facilitating breast
cancer metastasis to the lung (Qian et al., 2011). Clinical
evidence clearly associated elevated levels of CCL2 and
CCL5 with poor prognosis in breast, colon, prostate, and cervix
cancer patients due to metastatic progression (Soria et al.,
2011; Yoshidome et al., 2009; Zhang et al., 2010; Zijlmans
et al., 2006). Monocytes recruited to tumors through the
CCL2-CCR2 axis can be polarized to an alternatively activated
M2-phenotype thereby contributing to immunosuppression and
enhanced tumor cell survival (Loberg et al., 2007; Mantovani
and Sica, 2010). CCL2 has been shown to induce angiogenic
activation of endothelial cells along with inflammatory re-
sponses (Salcedo et al., 2000), and CCL2-mediated recruitment
of inflammatory monocytes promoted metastasis (Qian et al.,
2011). Similarly, overexpression of CCL2 in PC-3 prostate
cancer cells led to increased bone metastasis associated with
elevated accumulation of macrophages (Mizutani et al., 2009).
Consequently, CCL2-neutralizing antibody treatment signifi-
cantly prolonged survival of tumor-bearing mice due to inhibi-
tion of metastasis (Lu and Kang, 2009; Mizutani et al., 2009;
Qian et al., 2011; Salcedo et al., 2000). Although elevated(C) Flow cytometry analysis of monocytes in naive lungs of Ccr2/ and C57BL/
(D) Flow cytometry of CFP+ cells in blood and lung tissue of BacCCR2CFP transg
(E) Confocal microscopy analysis on lung tissue of C57BL/6 and BacCCR2GFPm
CD31 (red); nuclei are stained in blue (DAPI). The asterisk indicates the alveolar sp
are indicated.
(F) RT-PCR of Ccr2 expression in CD31-sorted primary endothelial cells isolated
shown (+RT), including controls without reverse transcriptase treatment (-RT). b-
(G) Time course analysis of tumor cell survival in lung tissue. Numbers of tumor ce
24 hr and 72 hr p.i. (n = 3, each; mean with min/max is shown). Statistics: ***p <
See also Figure S1.CCL2 expression is clearly linked to metastasis through
the recruitment of monocytes/macrophages, the exact mecha-
nisms by which CCL2 signaling facilitates tumor cell ex-
travasation at the endothelial barrier and subsequent metastatic
colonization remain elusive.
Here, we investigate the role of the CCL2-CCR2 chemokine
axis during metastatic dissemination and the involvement of
the endothelium in this process.
RESULTS
CCR2 Promotes Metastasis of Colon Carcinoma Cells
To determine whether tumor cell extravasation and growth was
altered in the absence of CCR2, C57BL/6 and Ccr2/ mice
were intravenously (i.v.) injected with syngeneic GFP+ colon
carcinoma cells (MC-38GFP) and lungs were macroscopically
scored for the presence of metastatic foci 28 days postinjection
(d.p.i.). Ccr2/ lungs displayed fewer tumors than C57BL/6
lungs (p < 0.001; Figure 1A; Figure S1A available online). Devel-
opment of tumors depended on CCR2 expression levels in the
recipient host, since Ccr2+/ lungs contained fewer metastases
than C57BL/6 (p < 0.01) but still more than Ccr2/ (p < 0.05;
Figures 1A, S1A, and S1B). This was corroborated by measure-
ment of relative GFP fluorescence in lung homogenates (Fig-
ure 1A). Immunohistochemistry revealed no obvious differences
in the relative composition of Ki67+, CD3+, F4/80+, and B220+
cells within the tumors (Figure 1B).
Next, we investigated whether differences in the immune
cell composition could influence metastasis. No differences in
numbers of CD4+ or CD8+ T cells, CD19+ B cells, NK1.1+, or
F4/80+ cells could be identified between naive C57BL/6 and
Ccr2/ lungs by flow cytometry (Figure S1C). However,Ccr2/
lungs displayed reduced numbers of CD11b+Ly6ChiLy6G
monocytes (p < 0.001; denoted as Ly6Chi) and a relative increase
in CD11b+Ly6G+ cells (p < 0.01; Figures 1C, S1D, and S1E). To
identify which cells express CCR2, we performed flow cytometry
on blood and lung tissue from BacCCR2CFP reporter mice, ex-
pressing CFP under the CCR2 promoter (Hohl et al., 2009).
Almost all CD11b+Ly6Chi cells were CFP positive, whereas
CD11b+Ly6G+, CD19+, CD4+, and CD8+ cells were CFP negative
(Figures 1D and S1F). We next investigated whether nonhemato-
poietic cells in lungs express CCR2. Confocal microscopy of
BacCCR2GFP mice revealed that CD31+ lung endothelial cells
expressed GFP (Figures 1E and S1G), as confirmed by transcrip-
tional analysis of purified primary endothelial cells from C57BL/6
and Ccr2/ lungs (Figures 1F, S1I, and S1J).
Altered numbers of colon carcinoma cells in lungs of Ccr2/
mice could explain the observed inability to form tumors.
However, no differences in the amount and distribution of6 mice.
enic mice shows that most Ly6Chi (red) but no Ly6G (blue) cells express CFP.
ice for the expression of GFP. Endothelial cells are positive for GFP (green) and
ace; scale bars: 20 mm (lowmagnification); 15 mm (highmagnification); Z-stacks
from lungs of C57BL/6 and Ccr2/mice. Two samples for each genotype are
actin served as control (bp, base pairs).
lls/view field were analyzed on sections of C57BL/6 and Ccr2/ lungs 30 min,
0.001; **p < 0.01; *p < 0.05; n.s., not significant.
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Figure 2. CCR2 Deficiency Reduces Tumor
Cell Extravasation and Vascular Perme-
ability and Affects Myeloid-Tumor Cell
Interaction
(A) Confocal microscopy of MC-38GFP cells
(green) and endothelial cells (red; lectin+) in
C57BL/6 and Ccr2/ lungs (n = 5) 24 hr p.i. with
MC-38GFP cells (upper row). Size of scale bar is
indicated. Three-dimensional reconstruction of the
interaction of both cell types (lower row). Quanti-
fication of the 3D contact area in voxels is shown
as percentiles.
(B) Macroscopy of naive C57BL/6 and Ccr2/
lungs (upper row) as well as 24 hr p.i. with MC-
38GFP cells (lower row) upon Evans blue admin-
istration. Size of scale bar is indicated. Spectro-
photometric quantification of Evans blue extracted
from C57BL/6 and Ccr2/ lungs (n = 6, each).
(C) Flow cytometry analysis for CD11b+Ly6Chi
cells in lung tissue upon tumor cell challenge of
C57BL/6 and Ccr2/ mice over time (left panel).
Quantification of Ly6Chi cells is presented in the
right panel (n = 6–7).
(D) Confocal microscopy images of the interaction
of myeloid cells (CD11b, F4/80, Ly6G, Ly6C; all
stained in red) with MC-38GFP cells (green) in
C57BL/6 and Ccr2/ mice 24 hr p.i. are shown.
Nuclei are stained in blue (DAPI; left panel).
Quantification of themyeloid-tumor cell interaction
in lungs; percentiles are indicated (n = 3, each).
Scale bar: 20 mm (right panel).
(E) Confocal microscopy analysis of the interac-
tion of adoptively transferred, PKH26-labeled
monocytes (green) with MC-38GFP cells (white)
and endogenous F4/80+ macrophages (red) in
C57BL/6 and Ccr2/ mice (n = 3) 16 hr p.i. (left
panel). Scale bar: 10 mm; Z-stacks are indicated.
Quantification of myeloid-tumor cell interaction in
lungs; percentiles are indicated (right panel; mean
with min/max). Statistics: ***p < 0.001; n.s., not
significant.
See also Figure S2.
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Tumor Cell-Derived CCL2 Controls MetastasisMC-38GFP cells in the lung vasculature were found in either
genotype as early as 30 min p.i. (Figure 1G). At later time points
(24, 72 hr), numbers of MC-38GFP cells in lung tissue decreased
in both genotypes, though slightly more pronounced in Ccr2/
mice at 24 hr. Besides, no significant changes were found in the
structure and organization of the CD31+ alveolar vasculature in
both genotypes (Figure S1H).94 Cancer Cell 22, 91–105, July 10, 2012 ª2012 Elsevier Inc.CCR2 Controls Endothelial
Permeability and Tumor Cell
Extravasation
Reduced lungmetastasis inCcr2/mice
could be explained by an impaired ability
of MC-38GFP cells to extravasate into
parenchyma of Ccr2/ lungs. Confocal
microscopy revealed that MC-38GFP
cells remained associated with tomato
lectin-stained endothelium of blood
vessels in Ccr2/ lungs at 24 hr p.i. (Fig-
ure 2A). In contrast, there was minimal
contact of MC-38GFP cells with endo-thelia in C57BL/6 mice at 24 hr p.i., indicating that tumor cells
had already extravasated from blood vessels. Three-dimen-
sional reconstruction of confocal images showed increased
contact of MC-38GFP cells with endothelium in Ccr2/ lungs
compared to C57BL/6 (p < 0.001; Figure 2A). To determine
whether reduced capacity of MC-38GFP cells to extravasate in
Ccr2/ lungs was due to decreased vascular permeability, we
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Tumor Cell-Derived CCL2 Controls Metastasistested the ability of Evans blue to permeate lung tissue. No Evans
blue leakage occurred in naive lungs of either genotype, indi-
cating full vascular integrity (Figure 2B). However, 24 hr p.i.
with MC-38GFP cells C57BL/6 lungs readily took up Evans
blue, whereas Ccr2/ lungs remained white, indicating no
increase in vascular permeability (Figure 2B). Quantification of
Evans blue confirmed the macroscopic data (p < 0.001; Figures
2B and S2C). The increase in vascular permeability upon injec-
tion of MC-38GFP cells was transient, as revealed by time
course analyses (Figures S2A and S2B).
Next, the hypothesis whether reduced capacity of MC-38GFP
cells to extravasate in Ccr2/ lungs correlates with reduced
recruitment of leukocytes was tested (La¨ubli et al., 2006; Qian
et al., 2011). Flow cytometry of lungs from mice injected with
MC-38GFP cells revealed recruitment of Ly6Chi cells in C57BL/
6 mice that was strongly reduced in Ccr2/ mice (Figure 2C).
The increase of Ly6Chi cells in C57BL/6 lungs persisted for
approximately 12–24 hr p.i. No significant increase of other
immune cell types (e.g., CD4+, CD8+, CD11c+, NK1.1+) was
found (data not shown).
In addition, we investigated whether lung-infiltrating myeloid
cell populations are recruited to MC-38GFP cells at sites of
vascular arrest. F4/80+, CD11b+, and Ly6C+ cells associated
less with tumor cells in Ccr2/ lungs compared to C57BL/6. In
contrast, increased association of Ly6G+ cells with MC-38GFP
cells was observed in Ccr2/ lungs (p < 0.001; Figure 2D).
Finally, to test whether MC-38GFP cells injected into Ccr2/
mice would still efficiently recruit myeloid cells, we adoptively
transferred myeloid cells to mice 6 hr post-tumor cell injection.
MC-38GFP cells recruited transferred myeloid cells in Ccr2/
but not in C57BL/6 lungs (p < 0.001; Figure 2E) as MC-38GFP
cells in C57BL/6 lungs had already recruited endogenous
myeloid cells.
CCR2 Expression on Radio-Resistant Cells Enables
Efficient Metastasis
We next tested whether reconstitution of Ccr2/ mice with
CCR2+ BM cells could restore the ability of MC-38GFP cells to
extravasate andmetastasize into lungs. Reciprocal BM reconsti-
tutions (C57BL/6/Ccr2/; Ccr2//C57BL/6) and controls
(C57BL/6/C57BL/6; Ccr2//Ccr2/) were performed and
blood was analyzed for the presence of CCR2+Ly6Chi mono-
cytes 6–8 weeks after reconstitution (Figures 3A and S3A).
MC-38GFP cells were administered to reconstituted mice (effi-
ciency >90%) and analyzed for tumor growth in lungs (Figures
3A and S3B). C57BL/6/C57BL/6mice displayed robust metas-
tasis similar to control C57BL/6 mice, whereas Ccr2//
Ccr2/ mice lacked or had strongly reduced metastasis.
CCR2 expression on radio-resistant cells (Ccr2//C57BL/6)
resulted in more metastasis when compared to mice devoid of
CCR2 expression in the stromal compartment (C57BL/6/
Ccr2/; p < 0.05). This indicates that both, hematopoietic and
stromal CCR2 expression is required for efficient metastasis.
To delineate the role of stromal CCR2 expression during
metastasis, we assessed whether endothelial cell-restricted
CCR2 expression (i.e., Tie2CCR2/Ccr2/ mice; (Mildner et al.,
2009) would enable tumor cell extravasation and metastasis.
Tie2CCR2/Ccr2/ mice lacked Ly6Chi monocytes in blood
and lung tissue and lacked CCR2 expression on CD11b+,CD19+ or CD3+ cells in blood, spleen and BM (Figures 3B
and S3C). Transcriptional analysis indicated Ccr2 expression in
whole lung tissue and in purified lung endothelial cells in
Tie2CCR2/Ccr2/ mice (Figures S3D and S3E). Upon injection
with MC-38GFP cells, tumor cell extravasation and metastasis
was partially restored in Tie2CCR2/Ccr2/ compared to
C57BL/6 mice (Figure 3C). Quantification of metastatic foci,
GFP fluorescence and immunohistochemistry confirmed these
data (Figures 3C, 3D, and S3F). Hence, expression of CCR2 on
endothelial cells was sufficient to partially restore metastasis.
CCR2Expression onMyeloid Cells Contributes to Tumor
Cell Metastasis
To assess the role of CCR2 on myeloid cells during metastasis,
we bred Ccr2loxP/loxP with LysMCre mice (Clausen et al., 1999),
resulting in mice with reduced CCR2 expression on myeloid
cells. Similar amounts of Ly6Chi monocytes were detected in
blood from LysMCreCcr2loxP/loxP and C57BL/6 mice by flow
cytometry (Figure 4A).
We next challenged LysMCreCcr2loxP/loxP mice with
MC-38GFP cells and quantified Ly6Chi monocytes in lungs at 6
and 12 hr p.i. (Figures 4B and S4A). Strong reduction (>90%) in
the influx of Ly6Chi monocytes to the lungs and a decrease in
local recruitment of F4/80+ and CD11b+ cells to tumor cells
were observed (Figure 4C). To determine the effect of re-
duced CCR2+/Ly6Chi monocyte recruitment on metastasis,
LysMCreCcr2loxP/loxP, Ccr2loxP/loxP, Ccr2/, and C57BL/6
mice were injected with MC-38GFP and analyzed 28 d.p.i.
Lung metastasis was increased in LysMCreCcr2loxP/loxP com-
pared to Ccr2/ mice (p < 0.05; Figures 4D and S4B).
However, in comparison to C57BL/6 mice, metastasis in
LysMCreCcr2loxP/loxP mice was decreased. This was confirmed
by quantification of GFP fluorescence and immunohistochem-
istry of lung tissues (Figures 4D and S4C). Thus, CCR2 expres-
sion on myeloid cells contributes to metastasis of MC-38GFP
cells.
Tumor Cell-Derived CCL2 Expression Controls Myeloid
Cell Recruitment
Whether CCR2-dependent lung metastasis occurs also with
different tumor cells, we injectedmicewith Lewis lung carcinoma
cells (3LL). Similar to MC-38GFP cells, attenuation of metastasis
was observed in Ccr2/when compared to C57BL/6 lungs (p <
0.05; Figure 5A, upper panels). Next, we injected B16-BL6
melanoma cells. Of note, similar extent of lung metastasis was
observed in C57BL/6 and Ccr2/ mice indicating that B16-
BL6melanoma cells extravasate andmetastasize independently
of CCR2 (Figure 5A, lower panels).
The dependency of metastasis on host-derived CCR2 expres-
sion indicates the involvement of tumor cell-intrinsic factors. We
therefore first compared chemokine and chemokine receptor
mRNA expression levels in lungs of C57BL/6 and Ccr2/ mice
injected with MC-38GFP cells. A strong increase in Ccl2, Ccl7,
Ccl12, Cxcl1, and Cxcl10 expression was detected at 4 hr p.i.
in C57BL/6 lungs (Figure 5B). These transcripts remained abun-
dant 8 and 12 hr p.i. and decreased at 48 hr p.i. (Figure 5B and
data not shown). Similar transcriptional changes occurred in
lungs of MC-38GFP-injected Ccr2/mice (Figure 5B), suggest-
ing that chemokine induction does not depend on host-derivedCancer Cell 22, 91–105, July 10, 2012 ª2012 Elsevier Inc. 95
Figure 3. CCR2 Expression on Radio-Resis-
tant Cells Suffices for Tumor Cell Metas-
tasis
(A) Flow cytometry analysis of blood from C57BL/
6/C57BL/6 (n = 8), C57BL/6/Ccr2/ (n = 9),
Ccr2//C57BL/6 (n = 7) and Ccr2//Ccr2/
(n = 5) chimeric mice for the presence of CCR2+
Ly6Chi cells (left row). Macroscopy of lungs from
MC-38GFP-injected chimeric mice 28 d.p.i. Size of
scale bar is indicated (middle/ right row).
(B) Flow cytometry for CD11b+Ly6Chi cells in blood
(upper row) and lungs (lower row) of naive
C57BL/6, Tie2CCR2/Ccr2/ and Ccr2/ mice
(left panel). Quantification of Ly6Chi cells is pre-
sented in the right panel (n = 6, each).
(C) Macroscopy of lungs fromMC-38GFP-injected
C57BL/6, Tie2CCR2/Ccr2/ andCcr2/mice 28
d.p.i. Size of scale bar is indicated (left panel).
Quantification of GFP fluorescence in lung
homogenates of C57BL/6, Tie2CCR2/Ccr2/ and
Ccr2/ mice (n = 5, each; right panel).
(D) Histological analysis of MC-38GFP tumors
in lungs of Tie2CCR2/Ccr2/ and Ccr2/ mice.
H&E: Hematoxylin/Eosin, GFP: tumor cells, Ki67:
proliferating cells, F4/80: macrophages. Scale bar:
50 mm; statistics: ***p < 0.001; **p < 0.01.
See also Figure S3.
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chemokine expression by altering the cellular composition and/
or activation status of cells in the lungs of MC-38GFP-injected
mice. However, chemokine receptor mRNA expression was96 Cancer Cell 22, 91–105, July 10, 2012 ª2012 Elsevier Inc.unaltered in lungs of C57BL/6 and
Ccr2/ mice p.i. (Figure 5C). When we
compared chemokine expression in MC-
38GFP, 3LL, and B16-BL6 cells, elevated
levels of Ccl2, Ccl7, Cxcl1, and Cxcl10
transcripts were detected in MC-38GFP
tumor cells compared to C57BL/6 colon
(Figure S5A). Of note, Ccl2 mRNA and
protein levels were elevated in MC-
38GFP and 3LL cells and low in B16-
BL6 melanoma cells, indicating that
CCR2-dependent metastasis relies on
tumor cell-derived CCL2 (Figures 5D,
S5B, and S5C).
To determine whether MC-38 and
3LL-derived CCL2 was required for tumor
cell extravasation and metastasis, CCL2
expression was silenced with small
hairpin RNA (shRNA) in MC-38GFP cells
(MC-38GFPCCL2kd). Ccl2 mRNA was re-
duced by 75%–90%, CCL2 protein was
reduced by 60%–85%, and expression
of other chemokines/cytokines remained
unaffected (Figure 5D). Cells stably trans-
duced with scrambled shRNA served as
control (MC-38GFPscr). MC-38GFP and
MC-38GFPCCL2kd cells were injected
into C57BL/6 mice, and their ability to
recruit Ly6Chi monocytes to the lung at 4and 12 hr p.i. was assayed by flow cytometry. Similar numbers
of Ly6Chi cells were detected at 4 hr p.i. in lungs of C57BL/6
mice injected with MC-38GFPCCL2kd or MC-38GFP cells (Fig-
ure 5E). However, no specific recruitment of Ly6Chi monocytes
Figure 4. CCR2 Expression on Ly6Chi Monocytes Facilitates Tumor Cell Extravasation
(A) Flow cytometry for CD11b+Ly6Chi cells in blood of C57BL/6, LysMCreCcr2loxP/loxP and Ccr2/ mice (n = 5–6; left panel). Quantification of Ly6Chi cells (right
panel).
(B) Flow cytometry for CD11b+Ly6Chi cells in lungs of naive C57BL/6 and MC-38-injected C57BL/6 and LysMCreCcr2loxP/loxP mice 12 hr p.i. (n = 5–7; left panel).
Quantification of Ly6Chi cells (right panel).
(C) Confocal microscopy investigating the interaction of myeloid cells (CD11b, F4/80; red) and tumor cells (green) in lungs of C57BL/6 and LysMCreCcr2loxP/loxP
mice. Nuclei are stained in blue (DAPI); scale bar: 20 mm; Z-stacks are indicated.
(D) Macroscopy of lungs fromC57BL/6, LysMCreCcr2loxP/loxP andCcr2/mice 28 d.p.i. with MC-38GFP. Size of scale bar is indicated (left panel). Quantification
of GFP fluorescence in lung homogenates of C57BL/6 (n = 5), LysMCreCCR2loxP/loxP (n = 6), and Ccr2/ (n = 6) mice (right panel). Statistics: ***p < 0.001;
*p < 0.05; n.s., not significant.
See also Figure S4.
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Figure 5. Tumor Cell-Derived CCL2-Dependent and -Independent Mechanisms of Tumor Cell Extravasation
(A) Macroscopy of lungs from C57BL/6 and Ccr2/ mice at 12 d.p.i. with Lewis lung carcinoma cells (3LL) and quantification of tumor nodules (n = 5, each;
upper row). Macroscopy of lungs from C57BL/6 and Ccr2/mice at 14 d.p.i. with melanoma cells (B16-BL6) and quantification of tumor numbers (n = 6, each;
lower row).
(B and C) Real-time PCR analysis for the expression of selected chemokines (B) and chemokine receptors (C) in lungs of C57BL/6 and Ccr2/mice. Untreated,
4 hr p.i., 8 hr p.i., and 12 hr p.i. with MC-38GFP are shown from left to right. Data are presented as DDct values in a log2 scale (red: upregulated; blue: down-
regulated). Columns indicate individual mice (n = 3); rows represent particular genes. Each data point reflects the median expression of a particular gene resulting
from three to four technical replicates, normalized to the mean expression value of the respective gene in C57BL/6 lungs.
(D) Expression profile of various chemokines and cytokines in MC-38GFP and MC-38GFPCCL2kd cells. 1: CCL2 (silenced); 2: CCL12; 3: CXCL10; 4: TIMP-1; 5:
CCL5 remain unaffected. Dots in the upper right and left corners serve as loading controls (left panel). Quantification of pixel density (shown in arbitrary units [a.u.];
mean ± SEM; right panel).
(E) Quantification of CD11b+Ly6Chi cells in lungs of naive C57BL/6 mice and 4 hr and 12 hr p.i. with MC-38GFP and MC-38GFPCCL2kd cells (n = 6–7).
(F) Macroscopy of lungs derived from C57BL/6 mice 28 d.p.i. with MC-38GFP, MC-38GFPscr and MC-38GFPCCL2kd cells. Size of scale bar is indicated.
Quantification of GFP fluorescence in lung homogenates of C57BL/6 mice 28 d.p.i. with MC-38GFP (n = 7), MC-38GFPscr (n = 6) and MC-38GFPCCL2kd (n = 9)
cells.
(G) Macroscopy of lungs fromC57BL/6mice 12 d.p.i. with 3LL and 3LLCCL2kd cells. Size of scale bar is indicated (left panel). Quantification of tumor nodules (n = 4,
each; right panel); statistics: ***p < 0.001; **p < 0.01; *p < 0.05; n.s., not significant.
See also Figure S5.
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38GFPCCL2kd cells. Therefore, specific recruitment of Ly6Chi
cells is controlled by MC-38-derived CCL2. Next, we analyzed98 Cancer Cell 22, 91–105, July 10, 2012 ª2012 Elsevier Inc.tumor cell extravasation and metastasis in C57BL/6 mice in-
jected withMC-38GFPCCL2kd, MC-38GFP orMC-38GFPscr cells.
Reduced lung metastasis was observed in C57BL/6 mice upon
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Tumor Cell-Derived CCL2 Controls MetastasisMC-38GFPCCL2kd injection and confirmed by analysis of GFP
fluorescence (p < 0.001; Figure 5F). Similar results were obtained
by silencing of CCL2 in 3LL cells (p < 0.01; Figure 5G).
In addition, reduced CCL2 expression in MC-38GFP
cells (MC-38GFPCCL2kd) diminished the ability to interact with
CD11b+, F4/80+, or Ly6C+ cells (p < 0.001). Although MC-
38GFPCCL2kd cells showed enhanced interaction with Ly6G+
cells (p < 0.001; Figure S5D), they failed to recruit adoptively
transferred myeloid cells (Figure S5E). This supports the conclu-
sion that tumor cell-derived CCL2 is required for the association
of tumor cells with myeloid cells.
CCR2 Expression on Endothelial Cells Determines Lung
Permeability
To determine whether endothelial CCR2 expression was suffi-
cient to induce vascular permeability, we injected Tie2CCR2/
Ccr2/ mice with MC-38GFP cells. Elevated levels of Evans
blue in Tie2CCR2/Ccr2/ lungs suggest that endothelial CCR2
activation is sufficient to induce lung vascular permeability (Fig-
ure 6A). Since host-derived CCL2 has been implicated in metas-
tasis (Qian et al., 2011), we injected Ccl2/ mice with MC-
38GFP cells. Interestingly, lung vascular permeability was
increased upon tumor cell injection (p < 0.001; Figure 6A), indi-
cating that tumor cells induce vascular permeability in the
absence of host-derived CCL2. In line, MC-38GFPCCL2kd cells
failed to induce vascular permeability in C57BL/6 lungs (Fig-
ure 6A). To investigate whether the local microenvironment
(e.g., CCL2 expression; monocytes; stromal cells) rescues the
inability of CCL2-deficient tumor cells to extravasate and metas-
tasize, we coinjected MC-38 and MC-38GFPCCL2kd cells into
C57BL/6 mice. Similar numbers of metastases were observed
in lungs of C57BL/6 mice injected with MC-38 versus MC-
38GFPCCL2kd/MC-38 cells 28 d.p.i. (p = 0.6; Figure 6B). Of
note, lungs from C57BL/6 mice injected with MC-38GFPCCL2kd/
MC-38 cells displayed mainly GFP-negative tumors, suggesting
that tumors mainly originated from CCL2+ tumor cells (p < 0.001;
Figures 6B and 6C). Therefore, the inability of MC-38GFPCCL2kd
cells tometastasize cannot be restored by the local environment.
We next examined lungs from C57BL/6 and Ccr2/ mice
12 hr p.i. with MC-38 cells at ultrastructural level. Injection of
MC-38 cells induced changes in C57BL/6 lung tissue including
increased thickness of airway epithelial cells in the bronchi and
thickened smooth muscle cells. Of note, tumor cells were found
inside the alveoli (Figure 6D, left panel) and rarely in the vessels.
Alveoli in C57BL/6 lungs appeared shrunken, with numerous
alveolar macrophages and type I, II pneumocytes. Moreover,
we observed an intimate interaction between MC-38 cells and
C57BL/6 endothelia with tumor cell protrusions spanning
through the apical side of the endothelium resembling ongoing
tumor cell transmigration (Figure 6D, middle panel, inset). In
contrast,Ccr2/ lung endothelium appeared to be less affected
by the injection of MC-38 tumor cells with no visible indication
for endothelial attachment (Figure 6D, right panel, inset).
Endothelial CCR2 Signaling Controls Tumor Cell
Extravasation through the JAK2-Stat5 and p38MAPK
Pathways
To identify the mechanisms involved in tumor cell extravasation,
we next examined transmigration of tumor cells through lungendothelial monolayers in presence or absence of monocytes
in vitro. MC-38GFP cells incubated on C57BL/6 endothelial cells
for 16 hr transmigrated only minimally toward an FCS gradient.
Cocultivation of MC-38GFP cells with BM-derived monocytes
induced efficient transmigration of MC-38GFP cells through
C57BL/6 endothelia (p < 0.001; Figure 7A). In contrast, MC-
38GFP cells were unable to transmigrate through endothelial
cells isolated from Ccr2/ mice either in the presence or ab-
sence of monocytes (p = 0.6; Figure 7A). To determine whether
tumor cell transmigration depends on tumor cell-derived
CCL2, we tested the ability of MC-38GFPCCL2kd cells to transmi-
grate in vitro. MC-38GFPCCL2kd cells could not transmigrate
through a C57BL/6 endothelial monolayer in the presence of
monocytes (p < 0.001; Figure 7B). Interestingly, neither lack of
endothelial nor monocytic CCR2 expression affected efficacy
of monocyte transmigration (Figure 7C). Taken together, endo-
thelial CCR2 signaling can specifically enable transmigration of
tumor cells without affecting monocytes. Tumor cell-derived
CCL2 was sufficient to induce permeability in the CCR2+ endo-
thelial monolayer even in the absence of monocytes. In contrast,
MC-38GFPCCL2kd cells induced partial endothelial permeability
only in the presence of monocytes (Figure 7D). These findings
provide direct evidence for the role of endothelial CCR2 activa-
tion during tumor cell extravasation; and for the supportive role
of monocytes in this process.
CCL2 is known to activate Janus kinase 2 (JAK2) through
CCR2 (Mellado et al., 1998), thereby triggering several down-
stream pathways such as Stat1, Stat3 and Stat5, p38MAPK,
and PI3K (Agrawal et al., 2011; Sanz-Moreno et al., 2011). We
first tested whether inhibition of JAK2 phosphorylation would
affect tumor cell transmigration. AG490 effectively blocked
tumor cell transmigration, demonstrating the requirement of
CCR2-JAK2 signaling for tumor cell extravasation (p < 0.001;
Figure 7E). Inhibition of Stat3 phosphorylation (S3I-201) failed
to affect tumor cell migration (p = 0.8), while block of Stat5
phosphorylation impeded transmigration of MC-38GFP cells
(p < 0.001; Figure 7E). PI3K inhibition with Wortmannin did not
alter tumor cell transmigration (p = 0.6), whereas blocking
p38MAPK phosphorylation with SB202190 did (p < 0.001, Fig-
ure 7F). Therefore, both JAK2-Stat5 and p38MAPK pathways
appeared to be involved in transmigration of MC-38GFP cells
through CCR2+ endothelium.
We next addressed whether tumor cells, rather than trans-
migrating through endothelial junctions, might trans-invade
endothelial cells (Feng et al., 1998), which was shown to
depend on Rac/Rho GTPases. However, inhibition of Rac1
(with NSC23766) failed to block tumor cell transmigration point-
ing at transmigration through endothelial junctions (Figure 7E).
To provide further evidence that CCR2-JAK2 signaling is
involved in tumor cell extravasation, we measured JAK2 phos-
phorylation in lung homogenates from MC-38-injected mice.
Increased JAK2 phosphorylation relative to total JAK2 was
observed at 8 and 12 hr p.i. in C57BL/6 lungs which was pre-
vented by AG490. In contrast, inhibition of p38MAPK did not
affect JAK2 phosphorylation (Figure 7F). Importantly, no orminor
phosphorylation of JAK2 was detected in Ccr2/ mice upon
tumor cell injection, confirming that CCR2 expression in lungs
is crucial for activation of this signaling cascade. Similarly,
p38MAPK and Stat5 were activated in lungs of C57BL/6 miceCancer Cell 22, 91–105, July 10, 2012 ª2012 Elsevier Inc. 99
Figure 6. Tumor Cell-Derived CCL2 Is Sufficient to Induce Endothelial Permeability
(A) Macroscopy of lungs with Evans blue accumulation derived from untreated C57BL/6 mice or treatedmice of various genotypes 24 hr p.i. with MC-38GFP and
MC-38GFPCCL2kd cells. Scale bar is indicated. Spectrophotometric quantification of Evans blue extracted from lung tissue.
(B) Macroscopy of lungs derived from C57BL/6 mice 28 d.p.i. with MC-38 (n = 3), MC-38/MC-38GFPCCL2kd (1:1 ratio; n = 5) andMC-38GFPCCL2kd cells (n = 3; left
panel). Quantification of tumor nodules on step cuts through lungs (blackbars representMC-38 cells, greenbarsMC-38GFPCCL2kd cells;mean±SEM; right panel).
(C) Immunohistochemistry for the quantification of tumor nodules. GFP and Ki67 served as tumor markers. Size of scale bar is indicated.
(D) Electron microscopy images of lungs of C57BL/6 (left and middle) and Ccr2/mice (right) 12 hr p.i. with MC-38GFP. Left: arrowhead points toward a tumor
cell in the alveolar space, in close contact to a type II pneumocyte (arrow). Middle panel: arrowhead shows an attached and transmigrating tumor cell localized
within the vessel. The arrow indicates a monocyte within the vessel. The insert shows the interaction between tumor cell and vessel wall at higher magnification.
Right: No visible transmigration of tumor cells (arrow head) in lungs of Ccr2/mice. Arrow: monocyte within the vessel. Scale bar: 5 mm; statistics: ***p < 0.001.
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Figure 7. CCL2-CCR2-Mediated Permeabilization of the Endothelium Is Driven by JAK2-Stat5 and p38MAPK activation
(A) MC-38GFP cells were cocultured with monocytes for 16 hr on monolayers of endothelial cells derived either from C57BL/6 or Ccr2/ lungs. Transmigrated
GFP+ tumor cells in the lower chamber were counted and are presented as percentiles (left panel). Representative images of transmigrated tumor cells for each
coculture; scale bar: 10 mm (right panel).
(B)MC-38GFP cells were comparedwithMC-38GFPCCL2kd cells for their efficiency tomigrate through C57BL/6 endothelial cells. TransmigratedGFP+ tumor cells
were counted and values are presented as percentiles.
(C) Analysis of transmigrated monocytes at 16 hr post coculture with C57BL/6 or Ccr2/ endothelial cells with or without tumor cells (mean ± SEM).
(D) Permeability of the C57BL/6 or Ccr2/ endothelial cell layer for Dextran-FITC was determined at 7 hr post addition of tumor cells with or without monocytes.
(E) Inhibitors for JAK2 (AG490), Rac (NSC23766), p38MAPK (SB201290), Stat3 (S3I-201), PI3K (Wortmannin), and Stat5 pathways were added to the coculture of
MC-38GFP cells with monocytes. GFP+ tumor cells transmigrated through the C57BL/6 endothelial cell layer were counted in the lower chamber.
(F) Immunoblot analysis of lung samples derived from C57BL/6 and Ccr2/ mice (untreated, 8 and 12 hr p.i.) as well as C57BL/6 mice treated with AG490 or
SB202190 (12 hr p.i.). Panel from top to bottom: pJAK2, JAK2, GAPDH, P-p38, p38, pStat5, Stat5, and GAPDH.
(G) Macroscopy of lungs upon Evans blue administration in presence or absence of inhibitors for Stat3, JAK2, Rac1, p38MAPK and Stat5 16 hr p.i. with MC-
38GFP cells. Quantification of Evans blue (n = 4, each; right panel; mean with min/max is shown). Statistics: ***p < 0.001; **p < 0.01; n.s., not significant.
See also Figure S6.
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Ccr2/ lungs (Figure 7F).
We next tested the involvement of the above-described
signaling pathways in controlling lung permeability. In line with
our in vitro data, JAK2, Stat5 and p38MAPK inhibition prevented
the increase in vascular permeability induced by MC-38GFP
cells in C57BL/6 mice. However, treatment with Rac1
(NSC23766) and Stat3 (S3I-201) inhibitor failed to affect vascular
permeability (Figure 7G). Since a specific inhibitor of PI3K did not
affect tumor cell transmigration in vitro, it is unlikely that PI3K
signaling is involved in tumor cell extravasation. Accordingly,
PI3Kg/ mice developed lung metastasis similar to C57BL/6
mice 28 d.p.i. of MC-38GFP cells (data not shown). Thus, inhibi-
tion of JAK2-Stat5 and p38MAPK signaling prevents tumor cell-
induced vascular permeability in vivo.
We next investigated whether JAK2-Stat5 or p38MAPK
inhibition exclusively affects endothelial cells or also monocytes.
We therefore analyzed levels of phosphorylated Stat5 and
p38MAPK in MC-38GFP-injected Tie2CCR2/Ccr2/ mice (Fig-
ures S6A and S6B). Increase in phosphorylation of JAK2,
Stat5 and p38MAPKwas comparable both in Tie2CCR2/Ccr2/
and C57BL/6 lungs. Therefore, Stat5 and p38MAPK activation in
endothelial cells occurs in the absence of Ly6Chi monocytes.
We next determined whether lack of CCR2 signaling in vivo
would affect the expression of Stat5 and p38MAPK target genes
associated with the vascular integrity of endothelial cells. Signif-
icantly decreased expression of E-selectin and Icam-1 (p < 0.05;
p < 0.001) was found in Ccr2/ lungs compared to C57BL/6
at 8 hr p.i. (Figure S6C). This suggested that the proinflammatory
endothelial response associated with metastasis was reduced
in Ccr2/ mice. Aside from these transcriptional changes, we
observed that coincubation of primary endothelial cells with
MC-38 cells caused cytoskeletal retraction and disruption of
the endothelial layer, as determined by phalloidin-fluorescein
isothiocyanate (FITC) staining (Figure S6D).
We next investigated on ultrastructural level, whether the inhi-
bition of CCR2 signaling affects tumor cell behavior in lungs of
C57BL/6 mice. In contrast to lungs of naive mice, but similar to
C57BL/6 tumor injected mice, thickened airway epithelial cells
and smooth muscle cells were found in mice treated with JAK2
inhibitor. However, strongly reduced tumor cell extravasation
could be observed in AG490 treated mice (Figure 8A).
Finally, we assessed whether JAK2 and p38MAPK inhibition
would also block lung metastasis. Thus, we treated MC-
38GFP-injected mice with AG490 or SB202190 during the first
3 d.p.i. Blockade of both, JAK2 and p38MAPK signaling attenu-
ated metastasis (p < 0.05; Figures 8B and 8C).
CCL2ExpressionCorrelateswithMetastatic Potential in
Human Colon Cancer Tissue
We next analyzed CCL2 expression in human primary nonme-
tastasized colon tumors (UICC stages I and II) and in colon
tumors that metastasized into the lymph nodes (UICC stage) or
into distant organs (UICC stage IV). CCL2 transcripts were
more abundant in primary colon tumors of stages I, II, and III
when compared to healthy colon samples. However, CCL2
expression was particularly high in colon tumors stage IV that
developed metastases in distant organs (Figure 8D), indicating
that upregulation of CCL2 correlates with metastatic potential.102 Cancer Cell 22, 91–105, July 10, 2012 ª2012 Elsevier Inc.DISCUSSION
During the multistep process of metastasis, cytokines and che-
mokines have been reported to have pro- or antitumorigenic
effects (Granot et al., 2011; Qian et al., 2011). Elevated CCL2
levels have been previously linked to malignancy and increased
metastasis in a number of cancers (Soria et al., 2011; Yoshi-
dome et al., 2009; Zhang et al., 2010; Zijlmans et al., 2006).
Our analysis of primary colon tumors (UICC stages I–IV)
confirmed the link between CCL2 upregulation in stage IV colon
carcinoma and metastatic capacity. Recent studies have shown
that monocyte recruitment by CCL2 contributes to lung metas-
tasis of breast cancer (Lu and Kang, 2009; Qian et al., 2011). Our
data provide evidence that tumor cell-derived CCL2 activates
CCR2 on endothelial cells, thereby enabling efficient tumor cell
extravasation.
To study the mechanisms of tumor cell extravasation, we
applied chimeric, transgenic, and knockout mice, as well as
in vitro assays. This allowed us to define the role of tumor cell-
derived CCL2 in a spatial and temporal manner. Using these
models, we determined that enhanced lung vascular perme-
ability, tumor cell extravasation, and recruitment of Ly6Chimono-
cytes are initiated by tumor cell-derived CCL2 at sites of vascular
arrest in a CCR2-dependent manner.
It was previously demonstrated that systemic depletion of
CCL2 with neutralizing antibodies could attenuate metastasis,
while the origin of CCL2 was identified to be in tumor cells and
stromal compartment (Qian et al., 2011). We show that vascular
permeability was enhanced in both Ccl2/ and C57BL/6 mice,
suggesting that host-derived CCL2 is not required. In addition,
silencing of CCL2 expression in two different tumor cell lines
(MC-38GFP and 3LL) prevented induction of lung vascular
permeability and subsequent metastasis, further demonstrating
that tumor cell-derived CCL2 is sufficient for initiation of tumor
cell extravasation. Previous observations that CCL2 overexpres-
sion in tumor cells enhanced metastasis are in line with our find-
ings (Lu and Kang, 2009). Importantly, recent work indicated that
CCR2 deficiency does not affect primary tumor growth (Sawano-
bori et al., 2008), arguing against the possibility that the observed
reduction in metastasis is the result of tumor growth rate.
Which cellular compartment integrates tumor cell-derived
CCL2 signaling through CCR2? CCL2-dependent recruitment
of monocytes to metastatic sites has been shown to contribute
to metastasis (Mizutani et al., 2009; Qian et al., 2011). It is also
known that CCL2-expressing breast tumor cells engage
CCR2+ cells of monocytic origin to facilitate colonization of
lung and bone (Lu and Kang, 2009). Consistent with this, we
show that recruitment of Ly6Chi monocytes correlates with
metastasis. However, depletion of CCR2 from monocytes in
LysMCreCcr2loxP/loxP mice strongly affected monocyte recruit-
ment and interaction with tumor cells and consequently reduced
but did not prevent metastasis. In line, even partial reduction of
CCR2 affected monocyte recruitment (Leuschner et al., 2011).
Accordingly, the number of metastases in Ccr2//C57BL/6
chimeric mice was considerably lower than in C57BL/6 mice.
Furthermore, experiments with Tie2CCR2/Ccr2/ mice con-
firmed that endothelial expression of CCR2 is sufficient for
metastasis (Figure 3C). Therefore, Ly6Chi monocytes appear to
be necessary but not sufficient for effective metastasis.
Figure 8. Short-Term Inhibition of JAK2 or p38MAPK Impedes Tumor Cell Metastasis
(A) Electron microscopy images of a naive C57BL/6 lung (left, scale bar: 4 mm) and 12 hr p.i. with MC-38GFP and AG490 treatment (right, scale bar: 2 mm); arrow
points toward a tumor cell.
(B)Macroscopy of lungs fromC57BL/6mice 26 d.p.i. withMC-38GFP left untreated or with AG490 or SB202190 treatment during the first 3 d.p.i. Scale bar: 5mm.
(C) Quantification of tumor nodules in lungs of C57BL/6 mice left untreated (n = 4), SB202190 (n = 3), or AG490 (n = 3) treated upon MC-38GFP injection.
(D) Transcriptional analysis of CCL2 levels in tissue obtained from colon-cancer patients.mRNA expression levels in healthy control tissue (ctrl.; n = 4), in tumor
samples classified as stage I (n = 10), stage II (n = 10) both being nonmetastatic; stage III: metastastic in lymph nodes (n = 10), stage IV: metastatic in distant
organs (n = 9) colon carcinomas were studied. Data are presented in a log2 scale. Each bar reflects the median expression (mean ± SEM) of a gene resulting from
three to four technical replicates, normalized to the mean expression value of CCL2 in control samples. Statistics: ***p < 0.001; **p < 0.01; *p < 0.05.
(E) Schematic model depicting how CCL2-expressing tumor cells attract monocytes (1 and 2), trigger vascular permeability (3) and transmigrate through the
endothelium (4). Tumor cell-dependent activation of CCR2 on the endothelium induces JAK2, Stat5, and p38MAPK phosphorylation but not PI3K, Stat3,
and Rac1.
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Tumor Cell-Derived CCL2 Controls MetastasisHere, we demonstrate that endothelial CCR2 signaling
controls metastasis by promoting tumor cell extravasation. We
hypothesize that CCR2 on endothelial cells may resemble
a ‘‘lock-and-key’’ signal for opening the vasculature and
enabling extravasation of CCL2+ tumor cells. Indeed, we found
that expression of CCR2 on endothelial cells is linked to the
induction of vascular permeability. This ‘‘lock-and-key’’ relation-
ship was dependent on CCL2 expression solely from the tumor
cells, since MC-38CCL2kd cells failed to induce vascular perme-
ability and metastasis in C57BL/6 mice. Since coinjection exper-
iments of MC-38GFPCCL2kd/MC-38 cells only induced efficient
metastasis of CCL2+ but not MC-38GFPCCL2kd cells, we suggest
that an intimate interaction of CCL2+ colon carcinoma cells with
the CCR2+ endothelium is required.
Monocyte transmigration still occurred through CCR2-defi-
cient endothelial monolayers, indicating that CCR2 signalingon endothelial cells specifically enables transmigration of
CCL2+ tumor cells.
There are several signaling pathways that participate in endo-
thelial activation associatedwith diapedesis of leukocytes during
inflammation (McIntyre et al., 2003), some of which act down-
stream of CCR2 (e.g., Stat3, PI3K (Yu et al., 2009). From the
panel of inhibitors tested in vitro, we identified the JAK2, Stat5,
and p38MAPK signaling pathways as responsible for induction
of vascular permeability and extravasation in vivo. Activation of
the p38MAPK in endothelial cells by transmigrating tumor cells
has been observed previously (Tremblay et al., 2006). The
pattern of JAK2 and p38MAPK activation in MC-38-injected
C57BL/6 mice suggests that these two pathways act in-
dependently of each other, since inhibition of p38MAPK phos-
phorylation did not block Stat5 or JAK2 phosphorylation. In
contrast, JAK2 inhibition blocked Stat5 but not p38MAPKCancer Cell 22, 91–105, July 10, 2012 ª2012 Elsevier Inc. 103
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JAK2-Stat5 and p38MAPK was detected in Tie2CCR2/Ccr2/
lungs, arguing that both signaling pathways are activated in
parallel in the endothelial compartment.
Based on our data, we propose the followingmodel describing
the role of CCR2 signaling in metastasis: Upon vascular arrest,
CCL2+ tumor cells induce a local chemokine gradient, recruiting
CCR2+ monocytes. Concomitantly or subsequently direct acti-
vation of CCR2 on the endothelium is triggered by tumor cells,
which is critical for metastasis. CCL2 activates JAK2 and
p38MAPK signaling, leading to enhanced vascular permeability
that along with monocyte recruitment enables efficient tumor
cell extravasation (Figure 8E). The exact kinetics and modes of
transmigration remain to be described. Our data identify a yet
undescribed role for tumor cell-derived chemokines in metas-
tasis that goes beyond the attraction of inflammatory cells.
With increasing interest, chemokines and chemokine recep-
tors are being considered as targets for cancer therapy,
including metastasis. Certainly, the CCL2-CCR2 axis is just
one possible chemokine-chemokine receptor axis exploited by
tumor cells. Nevertheless, further studies will be required to iden-
tify which cancers use chemokine-chemokine receptor interac-
tions for efficient tumor cell extravasation and metastasis. Our
results identify inhibition of CCR2 and its downstream targets
(JAK2/Stat5/p38MAPK) as a potential strategy for preventing
CCL2-mediated metastasis therapeutically.
EXPERIMENTAL PROCEDURES
Mice
Animals were maintained under specific pathogen-free conditions, and
experiments were approved by Zu¨rich Cantonal Veterinary Committee in
accordance to the guidelines of the Swiss Animal Protection Law. C57BL/6
and Ccl2/ mice were purchased from the Jackson Laboratory, Ccr2/
mice (Boring et al., 1997; Kuziel et al., 1997) were either purchased from the
Jackson Laboratory or obtained from our own breedings; Tie2CCR2/Ccr2/
were described previously (Mildner et al., 2009); LysMCreCcr2loxP/loxP were
obtained from M. Pasparakis (G.v.L. and M.P., unpublished data); and
BacCCR2GFP and BacCCR2DTCFP mice (Hohl et al., 2009) were obtained
from E. Pamer.
Human Colon Cancer Tissue
Patients with colon carcinomas stage UICC I (n = 10), II (n = 10), III (n = 10), and
IV (n = 9) were selected from the Erlangen Registry for Colorectal Carcinomas
(ERCRC). The local ethics committee approved the study and the regulations
of the same committee of the clinical center Erlangen were obeyed; written
consent has been obtained (approval nr. 3914).
Experimental Metastasis Assay
Mice were i.v. injected with MC-38GFP cells (3 3 105) and euthanized after
28 days. Metastatic foci were counted, macroscopic pictures of lungs were
taken and GFP fluorescence was measured in lung homogenates (Borsig
et al., 2002).
Vascular Permeability Assay
Permeability of the lungmicrovasculature was determinedwith Evans blue dye
extravasation technique (Reutershan et al., 2006). Briefly, mice were injected
with tumor cells, and, after 24 hr, 2 mg of Evans blue was i.v. injected followed
by euthanasia 30 min later. In experiments using various signaling pathways
inhibitors (AG490 and SB202190 [Sigma], NSC23766 [Calbiochem], S3I-201
and Stat5 [Santa Cruz]), inhibitors were i.p. injected 1 hr before and 5 hr
post tumor cell injection at concentrations of 10–25 mg/kg. Lungs were
perfused with PBS, dissected, photographed and homogenized. Evans blue
was extracted by incubation with formamide at 60C for 18 hr. Evans104 Cancer Cell 22, 91–105, July 10, 2012 ª2012 Elsevier Inc.blue concentration was measured spectrophotometrically (absorbance at
620 nm).
Statistical Analysis
Statistical analysis was performed with the GraphPad Prism software (version
4.0). All data are presented asmean ± SEM and were analyzed by ANOVAwith
the post hoc Bonferroni multiple comparison test, unless specified differently.
Analysis of two samples was performed with Student’s t test.
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